RxDoctor Payments Data

Chad Ahia, MD

Family Medicine · Honomu, HINPI 1417593831

Payments from drug & device makers

$656in general payments, 2019–2025

Across 31 payments — averaging $21.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$198
  • AbbVie$151
  • Pfizer$102
  • Novo Nordisk$97
  • Gilead$35
  • Lilly USA, LLC$26
  • plus $46 from 2 others

What the payments were for

  • Food & beverage$64498%
  • Education$122%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Amgen10$198
AbbVie6$151
Pfizer5$102
Novo Nordisk5$97
Gilead2$35
Lilly USA, LLC1$26
Genentech USA, Inc.1$24
Exact Sciences1$23

How this compares

$656 in reported general payments places this provider in the 65th percentile of 376 family medicine providers in Hawaii.

See all family medicine providers in Hawaii

Medicare billing

Part B allowed, 2024
$104,906
Medicare patients
184
Services billed
1,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban69$72,427
OzempicSemaglutide26$50,467
TrulicityDulaglutide19$47,296
JardianceEmpagliflozin29$41,903
RybelsusSemaglutide12$31,317
TivicayDolutegravir Sodium12$26,579
FarxigaDapagliflozin Propanediol12$19,682
XareltoRivaroxaban21$18,239
VascepaIcosapent Ethyl14$9,099
SymbicortBudesonide/Formoterol Fumarate24$8,711
Atorvastatin Calcium160$4,059
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$3,786
Rosuvastatin Calcium72$2,668
Losartan Potassium123$1,829
Ventolin HfaAlbuterol Sulfate14$1,757

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$97$81,78438 claims
PfizerEliquis$102$72,42769 claims
Lilly USA, LLCTrulicity$26$47,29619 claims
AbbVieSynthroid$151$1,58120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 376 family medicine providers in Hawaii.

Other family medicine in Honomu

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →